Skip to content
Thursday January 01, 1970
2:20 pmSector Analysis
Sector in focus: Medical aesthetics
This vast and fast-growing sector includes aesthetic procedures but also the treatment of age related conditions relating to dermatology, obesity, vein diseases, presbyopia and dental. Often this is an increasingly private pay market. We look at trends and growth rates across Europe.
Read more
Sector in focus: Medical aesthetics
This vast and fast-growing sector includes aesthetic procedures but also the treatment of age related conditions relating to dermatology, obesity, vein diseases, presbyopia and dental. Often this is an increasingly private pay market. We look at trends and growth rates across Europe.
Speakers
Explore similar sessions
1:30 pmPlenary
Getting the most out of your data
How are providers assessing and extracting value from their data? How do you best analyse it to improve outcomes and patient experience? And how do you best analyse it to...
Wolfgang HofmannGroup Head of Technology and InnovationFresenius Group
Getting the most out of your data
How are providers assessing and extracting value from their data? How do you best analyse it to improve outcomes and patient experience? And how do you best analyse it to optimise workflow and patient throughput? Three casestudies demonstrate what is possible and the pitfalls to avoid.
Speakers include:
Wolfgang Hofmann, Group head technology and innovation, Fresenius Group
Wolfgang will share how Fresenius is approaching digitalisation, implementing generative AI and moving to the cloud in the complexity of a large organisational structure.
Speakers
Wolfgang HofmannGroup Head of Technology and InnovationFresenius Group
9:30 amPlenary
The reawakening of nuclear medicine
Nuclear medicine long had its place in the diagnosis and treatment of disease, primarily in cardiology and oncology. Today, the nuclear medicine market is at an inflection point, as the...
Ian PoburennyDirector, HealthcareRothschild & Co
The reawakening of nuclear medicine
Nuclear medicine long had its place in the diagnosis and treatment of disease, primarily in cardiology and oncology. Today, the nuclear medicine market is at an inflection point, as the rise of theragnostics and the advent of novel products is expected to nearly quadruple the size of the market in the next 10 years from ~$7bn to $25+bn by 2033. The enormous growth in the field is driven by continued radiopharmaceutical funding where 250+ trials are currently being conducted and by trial funding increasing ~45%+ p.a. between 2019 and 2022. This session features perspectives from a provider, radiopharmaceutical group and OEM on how this is accelerating growth, shaping the market and discussing the medium and long-term obstacles.
Moderation and market overview: Ian Poburenny, Director, Healthcare, Rothschild & Co
Speakers
Ian PoburennyDirector, HealthcareRothschild & Co
2:50 pmPlenary
Building your patient pipeline: How consumerisation is changing the business model
As demand rises and capacity remains a challenge for the public sector globally, patients are turning to self-pay and private medical insurance. With this patients have shifted to become consumers,...
Justin AshCEOSpire
Charlie BullockCo-Founder & CEOScan.com
Building your patient pipeline: How consumerisation is changing the business model
As demand rises and capacity remains a challenge for the public sector globally, patients are turning to self-pay and private medical insurance. With this patients have shifted to become consumers, demanding speed, more control over their care pathway and a return on their own investment; increased quality and outcomes. This session features three CEOs who outline how consumerisation has led to new business models, strong brands and long-term patient engagement including how to best building really sticky apps.
Speakers include:
Justin Ash, CEO, Spire
Charlie Bullock, CEO, Scan.com
Speakers
Justin AshCEOSpire
Charlie BullockCo-Founder & CEOScan.com
Final discount saving ends in...
Days
Hours
Minutes
